Press

Medicenna to Present at 4th Annual Immuno-Oncology: BD&L and Investment Forum

TORONTO and HOUSTON, May 29, 2018 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQX: MDNAF), a clinical stage immuno-oncology company, is pleased to announce that executives from Medicenna will attend and present at the upcoming 4th Annual Sachs Immuno-Oncology: BD&L and Investment Forum being held on June 1, 2018 in Chicago, in parallel with the Annual Meeting of the American Society of Clinical Oncology (ASCO).

Dr. Fahar Merchant, President and CEO of Medicenna, will provide an overview of the Company, its most recent accomplishments and upcoming milestones with a focus on its IL-2 Superkine (MDNA109) and IL-4 Empowered Cytokine (MDNA55) programs. MDNA109, in pre-clinical development, is the only engineered IL-2 Superkine designed to specifically target CD122 (IL-2Rβ) without CD25 dependency. Unlike native IL-2, MDNA109 potently stimulates effector T cells, reverses Natural Killer (NK) cell anergy and acts with exceptional synergy when combined with checkpoint inhibitors. Lead selection of MDNA109 with extended half-life characteristics is currently underway. MDNA55, a fusion toxin targeting the IL-4R which is over-expressed in brain cancer and its immunosuppressive tumor micro-environment, is currently enrolling in a Phase 2b recurrent glioblastoma (rGBM) trial at major centers in the US.

Details of the June 1, 2018 presentation:

Sachs Associates 4th Annual Immuno-Oncology: BD&L and Investment Forum

Date: 

June 1, 2018

Time:

3:40 pm Central Time

Track:

B

Location:

Faulkner Room, Waldorf Astoria Chicago Hotel, Chicago, Illinois, USA

 

About Medicenna Therapeutics
Medicenna is a clinical stage immuno-oncology company developing novel highly selective versions of IL-2, IL-4 and IL-13 Superkines™ and first in class Empowered Cytokines™ (ECs).  Medicenna is specifically targeting the Interleukin-4 Receptor (IL4R), which is over-expressed by at least 20 different types of cancer affecting more than one million new cancer patients every year. A Phase 2b clinical trial for recurrent glioblastoma (rGBM) is enrolling patients at leading brain cancer centres in the US using Medicenna's lead candidate MDNA55. MDNA55 has completed 3 clinical trials in 72 patients, including 66 adults with rGBM, demonstrated compelling efficacy and obtained Fast-Track and Orphan Drug status from USFDA. Unlike most other cancer therapies, Medicenna's MDNA55 has the potential to purge both the tumor and the immunosuppressive tumor microenvironment, offering a unique treatment paradigm for a large majority of cancer patients.

For more information, please visit www.medicenna.com.

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the risks detailed in the annual information form of the Company dated June 15, 2017 and in other filings made by the Company with the applicable securities regulators from time to time.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements only as expressly required by Canadian securities law.

SOURCE Medicenna Therapeutics Corp.

For further information: about the Company please contact: Fahar Merchant, President and Chief Executive Officer, 604-671-6673, fmerchant@medicenna.com; Elizabeth Williams, Chief Financial Officer, 416-648-5555, ewilliams@medicenna.com; Media Contact: Mike Beyer, Sam Brown Inc., 1-312-961-2501, mikebeyer@sambrown.com
Investor Contact
For more investor information, Please contact:
 
Elizabeth Williams, Chief Financial Officer
 
 
Stock Quote
TSXMDNA
Email Alerts
* Required Fields